Analyst Rating Update on Clovis Oncology (CLVS)

Clovis Oncology (CLVS) : Zacks Investment Research ranks Clovis Oncology (CLVS) as 3, which is a Hold recommendation. 2 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 4 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 6 research analysts is 2.33, which indicates as a Buy.

Clovis Oncology (CLVS) : The highest short term price target forecast on Clovis Oncology (CLVS) is $30 and the lowest target price is $14. A total of 6 equity analysts are currently covering the company. The average price of all the analysts is $19.5 with a standard deviation of $6.16.

Company shares have received an average consensus rating of Hold for the current week


Clovis Oncology (NASDAQ:CLVS): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $14.62 and $14.62 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $15.35. The buying momentum continued till the end and the stock did not give up its gains. It closed at $15.23, notching a gain of 3.82% for the day. The total traded volume was 788,499 . The stock had closed at $14.67 on the previous day.

Clovis Oncology, Inc. (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase (PARP), is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3), vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *